0
2022
Opioid Use Disorder Market

Opioid Use Disorder Market

by Drug Type (Agonist, Antagonist), by Age group (19 to 39, 40 to 59, Age 60 and over), by Route of Administration (Oral, Intravenous, Sublingual), by Distribution channal (Hospital pharmacy, Retail Pharmacy): Global Opportunity Analysis and Industry Forecast, 2021-2031

Report Code: A12303
Aug 2022 | Pages: 324
Tables: 214
Charts: 68
  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.

 

Opioid Use Disorder Market Research, 2031

The global opioid use disorder market was valued at $2.8 billion in 2021, and is projected to reach $8.1 billion by 2031, growing at a CAGR of 11.5% from 2022 to 2031. Opioids are a group of painkillers that include drugs that relax muscles, reduce pain, and relieve stress. Medications including hydrocodone, oxycodone, codeine, fentanyl, methadone, morphine, and other pharmaceutical opioids are prescribed to relieve moderate- to severe pain. The chronic, relapsing brain illness known as opioid usage disorder (OUD) is characterized by excessive opioid seeking and use despite side effects. It is regarded as a brain condition because it involves functional changes to brain circuits related to motivation, stress, self-control, and decision-making, and because those changes may endure for a considerable amount of time after drug use has stopped. An overwhelming want to use opioids, increased opioid tolerance, and withdrawal symptoms after cessation are all symptoms of opioid use disorder.

The COVID-19 outbreak is anticipated to have a negative impact on growth of the global opioid use disorder market. The COVID-19 pandemic has stressed healthcare systems of the world. A huge number of clinics, hospitals across the globe, were restructured to increase the hospital capacity for the patient diagnosed with COVID-19. Moreover, the postponement or cancellation of doctor appointments has severely affected the market. Decrease in the number of scheduled surgeries anticipated to decrease in demand of opioids which cause decrease in the prevalence of opioid use disorder. Thus, these factors are anticipated to hinder the growth of market.

Growth of the global opioid use disorder market size is majorly driven by rise in the prevalence of chronic diseases such as cancer, cardiovascular diseases and orthopedic diseases anticipated to drive the opioid use disorder market growth. Increase in the number of chronic diseases cause rise in the incidence of surgical intervention. Opioid drugs are used to treat pain after surgery. This factor can cause addiction of opioid drugs even after decrease in pain. Thus, rise in the prevalence of chronic diseases anticipated fuel the demand of opioids use disorder drugs which boosts the market growth. For instance, as per the report of the National Cancer Institute, in 2020, an estimated 1,806,590 new cases of cancer were diagnosed in the U.S.

Opioid Use Disorder Market, Opioid Use Disorder Market size, Opioid Use Disorder Market share, Opioid Use Disorder Market trends, Opioid Use Disorder Market growth, Opioid Use Disorder Market analysis, Opioid Use Disorder Market forecast, Opioid Use Disorder Market opportunity

Moreover, rise in product launch and product approval for opioid use disorder drugs anticipated to fuel the growth of opioid use disorder market. For instance, in May 2020, Indivior PLC, a pharmaceutical company in U.S., announced the approval of Subutex from Swedish Medical Products Agency (MPA). Subutex prolonged release solution for injection, 100 and 300mg for substitution treatment of opioid dependence in adults and adolescents over 16 years of age. Moreover, in February 2019, Indivior PLC, a pharmaceutical company, announced the launch of generic version of SUBOXONE (buprenorphine and naloxone) Sublingual Film (CIII) in the U.S. used to treat opioid use disorders.

In addition, rising consideration of buprenorphine patches as an effective treatment mode fuels the market growth. Buprenorphine patches are becoming increasingly popular as an effective treatment for opioid use disorder, which is anticipated to the growth of opioid use disorder market. Patches containing buprenorphine are regarded as a cutting-edge method for treating opioid use disorder. Transdermal patches offer a number of benefits over other forms of treatment, such as injections, including the most pleasant drug delivery system, excellent pain relief, and self-administration of drug. In addition, rise in adoption of key strategies such as collaboration, acquisition, agreement and partnership by opioid industry of opioids use disorder fuels the growth of market. For instance, in February 2019, Indivior PLC, a pharmaceutical company, announced agreement with Alvogen Pine Brook LLC, a pharmaceutical company for sell of generic buprenorphine and naloxone sublingual film product unless and until the U.S. On the other hand, side effects associated opioids use disorder drugs anticipated to hinder the growth of opioid use disorder market growth.

Opioid Use Disorder Market Segmentation

The opioid use disorder market size is segmented into drug type, age group, route of administration and distribution channal, and region. On the basis of type, the market is segmented into agonist and antagonist. The agonist segment further sub-categorized into methadone and buprenorphine. Depending on age group, the market is classified into 19-39, 40-59 and age 60 and over. By route of administration, the market is classified into oral, intravenous and sublingual. On the basis of distribution channel, the market is divided into hospital pharmacy, retail pharmacy. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Segment Review

The agonist segment dominated the opioid use disorder market share in 2021, and is expected to continue this trend throughout the forecast period, owing to Rise in the prevalence of chronic pain, high prevalence of opioid abuse and rising geriatric population prone to painful disease. However, antagonist segment is expected to witness considerable growth during the opioid use disorder market forecast period, owing to increase in research & development expenditure by major players, strategic alliances among key companies, and ongoing research on naltrexone drugs.

Opioid Use Disorder Market

The 19 to 39 segment dominated the market in 2021, and is expected to continue this trend throughout the forecast period, owing to rise in the prevalence of chronic diseases such as cancer, cardiovascular diseases and orthopedic diseases associated with chronic pain.

Opioid Use Disorder Market

The intravenous segment dominated the market in 2021, and is expected to continue this trend throughout the forecast period, owing to rise in the demand of intravenous route for the treatment of opioids use disorder treatment.

Opioid Use Disorder Market

The hospital pharmacy segment dominated the market in 2021, and is expected to continue this trend throughout the forecast period, owing to rise in number of hospital pharmacy, increase in expenditure by government to develop healthcare infrastructure and increase in the prevalence of opioids use disorder.

Opioid Use Disorder Market

The North America market was dominant, in terms of revenue among other regions in 2021, owing to increase the number of product launch and product approval for opioids use disorder, increase in the prevalence of chronic diseases such as cancer, cardiac diseases and orthopedic diseases and well-established opioid industry in North America. On the other hand, Asia-Pacific was the second-largest contributor in the market in 2021, and is expected to register fastest CAGR during the forecast period, owing to the number of geriatric populations, rise in the awareness regarding availability of healthcare services and increase in the number of chronic diseases.      

Opioid Use Disorder Market

   

Some of the major companies that operate in the global opioid use disorder market include Alkermes, AstraZeneca Plc., BioDelivery Sciences International Inc., Braeburn, Camurus, Cerebral, Dr Reddy, Hikma Pharmaceuticals PLC, Indivior PLC, Mallinckrodt Pharmaceuticals, NYC Health + Hospitals, Orexo AB, Pear Therapeutics, Pfizer, Reckitt Benckiser Pharmaceuticals Inc., Sandoz (Novartis), Titan Pharmaceuticals, Inc., Viatris Inc.                          

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the opioid use disorder market analysis from 2021 to 2031 to identify the prevailing opioid use disorder market opportunity.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the opioid use disorder market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global opioid use disorder market trends, key players, market segments, application areas, and market growth strategies.

Opioid Use Disorder Market Report Highlights

Aspects Details
By Drug Type
  • Agonist
    • Type
      • Methadone
      • Buprenorphine
  • Antagonist
By Age group
  • 19 to 39
  • 40 to 59
  • Age 60 and over
By Route of Administration
  • Oral
  • Intravenous
  • Sublingual
By Distribution channal
  • Hospital pharmacy
  • Retail Pharmacy
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (Germany, France, UK, Italy, Spain, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, Australia, South Korea, Rest of Asia-Pacific)
  • LAMEA  (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
Key Market Players Dr Reddy Laboratories Ltd, Indivior PLC, Alkermes, Inc., AstraZeneca plc, mallinckrodt pharmaceuticals, Pear Therapeutics, OREXO AB, Camurus, Viatris Inc, Reckitt Benckiser Pharmaceuticals Inc, BioDelivery Sciences International Inc.,, Titan Pharmaceuticals, Inc., Orexo AB, Hikma Pharmaceuticals PLC,, braeburn pharmaceuticals, Sandoz, NYC Health Hospitals
 
  • CHAPTER 1:INTRODUCTION

    • 1.1.Report description

    • 1.2.Key market segments

    • 1.3.Key benefits to the stakeholders

    • 1.4.Research Methodology

      • 1.4.1.Secondary research

      • 1.4.2.Primary research

      • 1.4.3.Analyst tools and models

  • CHAPTER 2:EXECUTIVE SUMMARY

    • 2.1.Key findings of the study

    • 2.2.CXO Perspective

  • CHAPTER 3:MARKET OVERVIEW

    • 3.1.Market definition and scope

    • 3.2.Key findings

      • 3.2.1.Top investment pockets

    • 3.3.Porter’s five forces analysis

    • 3.4.Top player positioning

    • 3.5.Market dynamics

      • 3.5.1.Drivers

      • 3.5.2.Restraints

      • 3.5.3.Opportunities

    • 3.6.COVID-19 Impact Analysis on the market

  • CHAPTER 4: OPIOID USE DISORDER MARKET, BY DRUG TYPE

    • 4.1 Overview

      • 4.1.1 Market size and forecast

    • 4.2 Agonist

      • 4.2.1 Key market trends, growth factors and opportunities

      • 4.2.2 Market size and forecast, by region

      • 4.2.3 Market analysis by country

      • 4.2.4 Agonist Opioid Use Disorder Market by Type

        • 4.2.4.1 Methadone Market size and forecast, by region
        • 4.2.4.2 Buprenorphine Market size and forecast, by region
    • 4.3 Antagonist

      • 4.3.1 Key market trends, growth factors and opportunities

      • 4.3.2 Market size and forecast, by region

      • 4.3.3 Market analysis by country

  • CHAPTER 5: OPIOID USE DISORDER MARKET, BY AGE GROUP

    • 5.1 Overview

      • 5.1.1 Market size and forecast

    • 5.2 19 to 39

      • 5.2.1 Key market trends, growth factors and opportunities

      • 5.2.2 Market size and forecast, by region

      • 5.2.3 Market analysis by country

    • 5.3 40 to 59

      • 5.3.1 Key market trends, growth factors and opportunities

      • 5.3.2 Market size and forecast, by region

      • 5.3.3 Market analysis by country

    • 5.4 Age 60 and over

      • 5.4.1 Key market trends, growth factors and opportunities

      • 5.4.2 Market size and forecast, by region

      • 5.4.3 Market analysis by country

  • CHAPTER 6: OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION

    • 6.1 Overview

      • 6.1.1 Market size and forecast

    • 6.2 Oral

      • 6.2.1 Key market trends, growth factors and opportunities

      • 6.2.2 Market size and forecast, by region

      • 6.2.3 Market analysis by country

    • 6.3 Intravenous

      • 6.3.1 Key market trends, growth factors and opportunities

      • 6.3.2 Market size and forecast, by region

      • 6.3.3 Market analysis by country

    • 6.4 Sublingual

      • 6.4.1 Key market trends, growth factors and opportunities

      • 6.4.2 Market size and forecast, by region

      • 6.4.3 Market analysis by country

  • CHAPTER 7: OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNAL

    • 7.1 Overview

      • 7.1.1 Market size and forecast

    • 7.2 Hospital pharmacy

      • 7.2.1 Key market trends, growth factors and opportunities

      • 7.2.2 Market size and forecast, by region

      • 7.2.3 Market analysis by country

    • 7.3 Retail Pharmacy

      • 7.3.1 Key market trends, growth factors and opportunities

      • 7.3.2 Market size and forecast, by region

      • 7.3.3 Market analysis by country

  • CHAPTER 8: OPIOID USE DISORDER MARKET, BY REGION

    • 8.1 Overview

      • 8.1.1 Market size and forecast

    • 8.2 North America

      • 8.2.1 Key trends and opportunities

      • 8.2.2 North America Market size and forecast, by Drug Type

        • 8.2.2.1 North America Agonist Opioid Use Disorder Market by Type
      • 8.2.3 North America Market size and forecast, by Age group

      • 8.2.4 North America Market size and forecast, by Route of Administration

      • 8.2.5 North America Market size and forecast, by Distribution channal

      • 8.2.6 North America Market size and forecast, by country

        • 8.2.6.1 U.S.
          • 8.2.6.1.1 Market size and forecast, by Drug Type
          • 8.2.6.1.2 Market size and forecast, by Age group
          • 8.2.6.1.3 Market size and forecast, by Route of Administration
          • 8.2.6.1.4 Market size and forecast, by Distribution channal
        • 8.2.6.2 Canada
          • 8.2.6.2.1 Market size and forecast, by Drug Type
          • 8.2.6.2.2 Market size and forecast, by Age group
          • 8.2.6.2.3 Market size and forecast, by Route of Administration
          • 8.2.6.2.4 Market size and forecast, by Distribution channal
        • 8.2.6.3 Mexico
          • 8.2.6.3.1 Market size and forecast, by Drug Type
          • 8.2.6.3.2 Market size and forecast, by Age group
          • 8.2.6.3.3 Market size and forecast, by Route of Administration
          • 8.2.6.3.4 Market size and forecast, by Distribution channal
    • 8.3 Europe

      • 8.3.1 Key trends and opportunities

      • 8.3.2 Europe Market size and forecast, by Drug Type

        • 8.3.2.1 Europe Agonist Opioid Use Disorder Market by Type
      • 8.3.3 Europe Market size and forecast, by Age group

      • 8.3.4 Europe Market size and forecast, by Route of Administration

      • 8.3.5 Europe Market size and forecast, by Distribution channal

      • 8.3.6 Europe Market size and forecast, by country

        • 8.3.6.1 Germany
          • 8.3.6.1.1 Market size and forecast, by Drug Type
          • 8.3.6.1.2 Market size and forecast, by Age group
          • 8.3.6.1.3 Market size and forecast, by Route of Administration
          • 8.3.6.1.4 Market size and forecast, by Distribution channal
        • 8.3.6.2 France
          • 8.3.6.2.1 Market size and forecast, by Drug Type
          • 8.3.6.2.2 Market size and forecast, by Age group
          • 8.3.6.2.3 Market size and forecast, by Route of Administration
          • 8.3.6.2.4 Market size and forecast, by Distribution channal
        • 8.3.6.3 UK
          • 8.3.6.3.1 Market size and forecast, by Drug Type
          • 8.3.6.3.2 Market size and forecast, by Age group
          • 8.3.6.3.3 Market size and forecast, by Route of Administration
          • 8.3.6.3.4 Market size and forecast, by Distribution channal
        • 8.3.6.4 Italy
          • 8.3.6.4.1 Market size and forecast, by Drug Type
          • 8.3.6.4.2 Market size and forecast, by Age group
          • 8.3.6.4.3 Market size and forecast, by Route of Administration
          • 8.3.6.4.4 Market size and forecast, by Distribution channal
        • 8.3.6.5 Spain
          • 8.3.6.5.1 Market size and forecast, by Drug Type
          • 8.3.6.5.2 Market size and forecast, by Age group
          • 8.3.6.5.3 Market size and forecast, by Route of Administration
          • 8.3.6.5.4 Market size and forecast, by Distribution channal
        • 8.3.6.6 Rest of Europe
          • 8.3.6.6.1 Market size and forecast, by Drug Type
          • 8.3.6.6.2 Market size and forecast, by Age group
          • 8.3.6.6.3 Market size and forecast, by Route of Administration
          • 8.3.6.6.4 Market size and forecast, by Distribution channal
    • 8.4 Asia-Pacific

      • 8.4.1 Key trends and opportunities

      • 8.4.2 Asia-Pacific Market size and forecast, by Drug Type

        • 8.4.2.1 Asia-Pacific Agonist Opioid Use Disorder Market by Type
      • 8.4.3 Asia-Pacific Market size and forecast, by Age group

      • 8.4.4 Asia-Pacific Market size and forecast, by Route of Administration

      • 8.4.5 Asia-Pacific Market size and forecast, by Distribution channal

      • 8.4.6 Asia-Pacific Market size and forecast, by country

        • 8.4.6.1 China
          • 8.4.6.1.1 Market size and forecast, by Drug Type
          • 8.4.6.1.2 Market size and forecast, by Age group
          • 8.4.6.1.3 Market size and forecast, by Route of Administration
          • 8.4.6.1.4 Market size and forecast, by Distribution channal
        • 8.4.6.2 Japan
          • 8.4.6.2.1 Market size and forecast, by Drug Type
          • 8.4.6.2.2 Market size and forecast, by Age group
          • 8.4.6.2.3 Market size and forecast, by Route of Administration
          • 8.4.6.2.4 Market size and forecast, by Distribution channal
        • 8.4.6.3 India
          • 8.4.6.3.1 Market size and forecast, by Drug Type
          • 8.4.6.3.2 Market size and forecast, by Age group
          • 8.4.6.3.3 Market size and forecast, by Route of Administration
          • 8.4.6.3.4 Market size and forecast, by Distribution channal
        • 8.4.6.4 Australia
          • 8.4.6.4.1 Market size and forecast, by Drug Type
          • 8.4.6.4.2 Market size and forecast, by Age group
          • 8.4.6.4.3 Market size and forecast, by Route of Administration
          • 8.4.6.4.4 Market size and forecast, by Distribution channal
        • 8.4.6.5 South Korea
          • 8.4.6.5.1 Market size and forecast, by Drug Type
          • 8.4.6.5.2 Market size and forecast, by Age group
          • 8.4.6.5.3 Market size and forecast, by Route of Administration
          • 8.4.6.5.4 Market size and forecast, by Distribution channal
        • 8.4.6.6 Rest of Asia-Pacific
          • 8.4.6.6.1 Market size and forecast, by Drug Type
          • 8.4.6.6.2 Market size and forecast, by Age group
          • 8.4.6.6.3 Market size and forecast, by Route of Administration
          • 8.4.6.6.4 Market size and forecast, by Distribution channal
    • 8.5 LAMEA

      • 8.5.1 Key trends and opportunities

      • 8.5.2 LAMEA Market size and forecast, by Drug Type

        • 8.5.2.1 LAMEA Agonist Opioid Use Disorder Market by Type
      • 8.5.3 LAMEA Market size and forecast, by Age group

      • 8.5.4 LAMEA Market size and forecast, by Route of Administration

      • 8.5.5 LAMEA Market size and forecast, by Distribution channal

      • 8.5.6 LAMEA Market size and forecast, by country

        • 8.5.6.1 Brazil
          • 8.5.6.1.1 Market size and forecast, by Drug Type
          • 8.5.6.1.2 Market size and forecast, by Age group
          • 8.5.6.1.3 Market size and forecast, by Route of Administration
          • 8.5.6.1.4 Market size and forecast, by Distribution channal
        • 8.5.6.2 Saudi Arabia
          • 8.5.6.2.1 Market size and forecast, by Drug Type
          • 8.5.6.2.2 Market size and forecast, by Age group
          • 8.5.6.2.3 Market size and forecast, by Route of Administration
          • 8.5.6.2.4 Market size and forecast, by Distribution channal
        • 8.5.6.3 South Africa
          • 8.5.6.3.1 Market size and forecast, by Drug Type
          • 8.5.6.3.2 Market size and forecast, by Age group
          • 8.5.6.3.3 Market size and forecast, by Route of Administration
          • 8.5.6.3.4 Market size and forecast, by Distribution channal
        • 8.5.6.4 Rest of LAMEA
          • 8.5.6.4.1 Market size and forecast, by Drug Type
          • 8.5.6.4.2 Market size and forecast, by Age group
          • 8.5.6.4.3 Market size and forecast, by Route of Administration
          • 8.5.6.4.4 Market size and forecast, by Distribution channal
  • CHAPTER 9: COMPANY LANDSCAPE

    • 9.1. Introduction

    • 9.2. Top winning strategies

    • 9.3. Product Mapping of Top 10 Player

    • 9.4. Competitive Dashboard

    • 9.5. Competitive Heatmap

    • 9.6. Key developments

  • CHAPTER 10: COMPANY PROFILES

    • 10.1 Alkermes, Inc.

      • 10.1.1 Company overview

      • 10.1.2 Company snapshot

      • 10.1.3 Operating business segments

      • 10.1.4 Product portfolio

      • 10.1.5 Business performance

      • 10.1.6 Key strategic moves and developments

    • 10.2 AstraZeneca plc

      • 10.2.1 Company overview

      • 10.2.2 Company snapshot

      • 10.2.3 Operating business segments

      • 10.2.4 Product portfolio

      • 10.2.5 Business performance

      • 10.2.6 Key strategic moves and developments

    • 10.3 BioDelivery Sciences International Inc.,

      • 10.3.1 Company overview

      • 10.3.2 Company snapshot

      • 10.3.3 Operating business segments

      • 10.3.4 Product portfolio

      • 10.3.5 Business performance

      • 10.3.6 Key strategic moves and developments

    • 10.4 braeburn pharmaceuticals

      • 10.4.1 Company overview

      • 10.4.2 Company snapshot

      • 10.4.3 Operating business segments

      • 10.4.4 Product portfolio

      • 10.4.5 Business performance

      • 10.4.6 Key strategic moves and developments

    • 10.5 Camurus

      • 10.5.1 Company overview

      • 10.5.2 Company snapshot

      • 10.5.3 Operating business segments

      • 10.5.4 Product portfolio

      • 10.5.5 Business performance

      • 10.5.6 Key strategic moves and developments

    • 10.6 Dr Reddy Laboratories Ltd

      • 10.6.1 Company overview

      • 10.6.2 Company snapshot

      • 10.6.3 Operating business segments

      • 10.6.4 Product portfolio

      • 10.6.5 Business performance

      • 10.6.6 Key strategic moves and developments

    • 10.7 Pear Therapeutics

      • 10.7.1 Company overview

      • 10.7.2 Company snapshot

      • 10.7.3 Operating business segments

      • 10.7.4 Product portfolio

      • 10.7.5 Business performance

      • 10.7.6 Key strategic moves and developments

    • 10.8 Hikma Pharmaceuticals PLC,

      • 10.8.1 Company overview

      • 10.8.2 Company snapshot

      • 10.8.3 Operating business segments

      • 10.8.4 Product portfolio

      • 10.8.5 Business performance

      • 10.8.6 Key strategic moves and developments

    • 10.9 mallinckrodt pharmaceuticals

      • 10.9.1 Company overview

      • 10.9.2 Company snapshot

      • 10.9.3 Operating business segments

      • 10.9.4 Product portfolio

      • 10.9.5 Business performance

      • 10.9.6 Key strategic moves and developments

    • 10.10 NYC Health Hospitals

      • 10.10.1 Company overview

      • 10.10.2 Company snapshot

      • 10.10.3 Operating business segments

      • 10.10.4 Product portfolio

      • 10.10.5 Business performance

      • 10.10.6 Key strategic moves and developments

    • 10.11 Orexo AB

      • 10.11.1 Company overview

      • 10.11.2 Company snapshot

      • 10.11.3 Operating business segments

      • 10.11.4 Product portfolio

      • 10.11.5 Business performance

      • 10.11.6 Key strategic moves and developments

    • 10.12 OREXO AB

      • 10.12.1 Company overview

      • 10.12.2 Company snapshot

      • 10.12.3 Operating business segments

      • 10.12.4 Product portfolio

      • 10.12.5 Business performance

      • 10.12.6 Key strategic moves and developments

    • 10.13 Indivior PLC

      • 10.13.1 Company overview

      • 10.13.2 Company snapshot

      • 10.13.3 Operating business segments

      • 10.13.4 Product portfolio

      • 10.13.5 Business performance

      • 10.13.6 Key strategic moves and developments

    • 10.14 Reckitt Benckiser Pharmaceuticals Inc

      • 10.14.1 Company overview

      • 10.14.2 Company snapshot

      • 10.14.3 Operating business segments

      • 10.14.4 Product portfolio

      • 10.14.5 Business performance

      • 10.14.6 Key strategic moves and developments

    • 10.15 Sandoz

      • 10.15.1 Company overview

      • 10.15.2 Company snapshot

      • 10.15.3 Operating business segments

      • 10.15.4 Product portfolio

      • 10.15.5 Business performance

      • 10.15.6 Key strategic moves and developments

    • 10.16 Titan Pharmaceuticals, Inc.

      • 10.16.1 Company overview

      • 10.16.2 Company snapshot

      • 10.16.3 Operating business segments

      • 10.16.4 Product portfolio

      • 10.16.5 Business performance

      • 10.16.6 Key strategic moves and developments

    • 10.17 Viatris Inc

      • 10.17.1 Company overview

      • 10.17.2 Company snapshot

      • 10.17.3 Operating business segments

      • 10.17.4 Product portfolio

      • 10.17.5 Business performance

      • 10.17.6 Key strategic moves and developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 2. OPIOID USE DISORDER MARKET SIZE, FOR AGONIST, BY REGION, 2021-2031 ($MILLION)
    TABLE 3. OPIOID USE DISORDER MARKET FOR AGONIST, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 4. GLOBAL AGONIST OPIOID USE DISORDER MARKET, BY TYPE, 2021-2031 ($MILLION)
    TABLE 5. OPIOID USE DISORDER MARKET, FOR METHADONE, BY REGION, 2021-2031 ($MILLION)
    TABLE 6. OPIOID USE DISORDER MARKET, FOR BUPRENORPHINE, BY REGION, 2021-2031 ($MILLION)
    TABLE 7. OPIOID USE DISORDER MARKET SIZE, FOR ANTAGONIST, BY REGION, 2021-2031 ($MILLION)
    TABLE 8. OPIOID USE DISORDER MARKET FOR ANTAGONIST, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 9. GLOBAL OPIOID USE DISORDER MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
    TABLE 10. OPIOID USE DISORDER MARKET SIZE, FOR 19 TO 39, BY REGION, 2021-2031 ($MILLION)
    TABLE 11. OPIOID USE DISORDER MARKET FOR 19 TO 39, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 12. OPIOID USE DISORDER MARKET SIZE, FOR 40 TO 59, BY REGION, 2021-2031 ($MILLION)
    TABLE 13. OPIOID USE DISORDER MARKET FOR 40 TO 59, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 14. OPIOID USE DISORDER MARKET SIZE, FOR AGE 60 AND OVER, BY REGION, 2021-2031 ($MILLION)
    TABLE 15. OPIOID USE DISORDER MARKET FOR AGE 60 AND OVER, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 16. GLOBAL OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
    TABLE 17. OPIOID USE DISORDER MARKET SIZE, FOR ORAL, BY REGION, 2021-2031 ($MILLION)
    TABLE 18. OPIOID USE DISORDER MARKET FOR ORAL, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 19. OPIOID USE DISORDER MARKET SIZE, FOR INTRAVENOUS, BY REGION, 2021-2031 ($MILLION)
    TABLE 20. OPIOID USE DISORDER MARKET FOR INTRAVENOUS, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 21. OPIOID USE DISORDER MARKET SIZE, FOR SUBLINGUAL, BY REGION, 2021-2031 ($MILLION)
    TABLE 22. OPIOID USE DISORDER MARKET FOR SUBLINGUAL, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 23. GLOBAL OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNAL, 2021-2031 ($MILLION)
    TABLE 24. OPIOID USE DISORDER MARKET SIZE, FOR HOSPITAL PHARMACY, BY REGION, 2021-2031 ($MILLION)
    TABLE 25. OPIOID USE DISORDER MARKET FOR HOSPITAL PHARMACY, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 26. OPIOID USE DISORDER MARKET SIZE, FOR RETAIL PHARMACY, BY REGION, 2021-2031 ($MILLION)
    TABLE 27. OPIOID USE DISORDER MARKET FOR RETAIL PHARMACY, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 28. OPIOID USE DISORDER MARKET, BY REGION, 2021-2031 ($MILLION)
    TABLE 29. NORTH AMERICA OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 30. NORTH AMERICA AGONIST OPIOID USE DISORDER MARKET, BY TYPE, 2021-2031 ($MILLION)
    TABLE 31. NORTH AMERICA OPIOID USE DISORDER MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
    TABLE 32. NORTH AMERICA OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
    TABLE 33. NORTH AMERICA OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNAL, 2021-2031 ($MILLION)
    TABLE 34. NORTH AMERICA OPIOID USE DISORDER MARKET, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 35. U.S. OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 36. U.S. OPIOID USE DISORDER MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
    TABLE 37. U.S. OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
    TABLE 38. U.S. OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNAL, 2021-2031 ($MILLION)
    TABLE 39. CANADA OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 40. CANADA OPIOID USE DISORDER MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
    TABLE 41. CANADA OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
    TABLE 42. CANADA OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNAL, 2021-2031 ($MILLION)
    TABLE 43. MEXICO OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 44. MEXICO OPIOID USE DISORDER MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
    TABLE 45. MEXICO OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
    TABLE 46. MEXICO OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNAL, 2021-2031 ($MILLION)
    TABLE 47. EUROPE OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 48. EUROPE AGONIST OPIOID USE DISORDER MARKET, BY TYPE, 2021-2031 ($MILLION)
    TABLE 49. EUROPE OPIOID USE DISORDER MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
    TABLE 50. EUROPE OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
    TABLE 51. EUROPE OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNAL, 2021-2031 ($MILLION)
    TABLE 52. EUROPE OPIOID USE DISORDER MARKET, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 53. GERMANY OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 54. GERMANY OPIOID USE DISORDER MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
    TABLE 55. GERMANY OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
    TABLE 56. GERMANY OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNAL, 2021-2031 ($MILLION)
    TABLE 57. FRANCE OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 58. FRANCE OPIOID USE DISORDER MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
    TABLE 59. FRANCE OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
    TABLE 60. FRANCE OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNAL, 2021-2031 ($MILLION)
    TABLE 61. UK OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 62. UK OPIOID USE DISORDER MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
    TABLE 63. UK OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
    TABLE 64. UK OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNAL, 2021-2031 ($MILLION)
    TABLE 65. ITALY OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 66. ITALY OPIOID USE DISORDER MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
    TABLE 67. ITALY OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
    TABLE 68. ITALY OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNAL, 2021-2031 ($MILLION)
    TABLE 69. SPAIN OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 70. SPAIN OPIOID USE DISORDER MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
    TABLE 71. SPAIN OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
    TABLE 72. SPAIN OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNAL, 2021-2031 ($MILLION)
    TABLE 73. REST OF EUROPE OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 74. REST OF EUROPE OPIOID USE DISORDER MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
    TABLE 75. REST OF EUROPE OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
    TABLE 76. REST OF EUROPE OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNAL, 2021-2031 ($MILLION)
    TABLE 77. ASIA-PACIFIC OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 78. ASIA-PACIFIC AGONIST OPIOID USE DISORDER MARKET, BY TYPE, 2021-2031 ($MILLION)
    TABLE 79. ASIA-PACIFIC OPIOID USE DISORDER MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
    TABLE 80. ASIA-PACIFIC OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
    TABLE 81. ASIA-PACIFIC OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNAL, 2021-2031 ($MILLION)
    TABLE 82. ASIA-PACIFIC OPIOID USE DISORDER MARKET, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 83. CHINA OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 84. CHINA OPIOID USE DISORDER MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
    TABLE 85. CHINA OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
    TABLE 86. CHINA OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNAL, 2021-2031 ($MILLION)
    TABLE 87. JAPAN OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 88. JAPAN OPIOID USE DISORDER MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
    TABLE 89. JAPAN OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
    TABLE 90. JAPAN OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNAL, 2021-2031 ($MILLION)
    TABLE 91. INDIA OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 92. INDIA OPIOID USE DISORDER MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
    TABLE 93. INDIA OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
    TABLE 94. INDIA OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNAL, 2021-2031 ($MILLION)
    TABLE 95. AUSTRALIA OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 96. AUSTRALIA OPIOID USE DISORDER MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
    TABLE 97. AUSTRALIA OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
    TABLE 98. AUSTRALIA OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNAL, 2021-2031 ($MILLION)
    TABLE 99. SOUTH KOREA OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 100. SOUTH KOREA OPIOID USE DISORDER MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
    TABLE 101. SOUTH KOREA OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
    TABLE 102. SOUTH KOREA OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNAL, 2021-2031 ($MILLION)
    TABLE 103. REST OF ASIA-PACIFIC OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 104. REST OF ASIA-PACIFIC OPIOID USE DISORDER MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
    TABLE 105. REST OF ASIA-PACIFIC OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
    TABLE 106. REST OF ASIA-PACIFIC OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNAL, 2021-2031 ($MILLION)
    TABLE 107. LAMEA OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 108. LAMEA AGONIST OPIOID USE DISORDER MARKET, BY TYPE, 2021-2031 ($MILLION)
    TABLE 109. LAMEA OPIOID USE DISORDER MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
    TABLE 110. LAMEA OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
    TABLE 111. LAMEA OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNAL, 2021-2031 ($MILLION)
    TABLE 112. LAMEA OPIOID USE DISORDER MARKET, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 113. BRAZIL OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 114. BRAZIL OPIOID USE DISORDER MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
    TABLE 115. BRAZIL OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
    TABLE 116. BRAZIL OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNAL, 2021-2031 ($MILLION)
    TABLE 117. SAUDI ARABIA OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 118. SAUDI ARABIA OPIOID USE DISORDER MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
    TABLE 119. SAUDI ARABIA OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
    TABLE 120. SAUDI ARABIA OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNAL, 2021-2031 ($MILLION)
    TABLE 121. SOUTH AFRICA OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 122. SOUTH AFRICA OPIOID USE DISORDER MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
    TABLE 123. SOUTH AFRICA OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
    TABLE 124. SOUTH AFRICA OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNAL, 2021-2031 ($MILLION)
    TABLE 125. REST OF LAMEA OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
    TABLE 126. REST OF LAMEA OPIOID USE DISORDER MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
    TABLE 127. REST OF LAMEA OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
    TABLE 128. REST OF LAMEA OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNAL, 2021-2031 ($MILLION)
    TABLE 129.ALKERMES, INC.: COMPANY SNAPSHOT
    TABLE 130.ALKERMES, INC.: OPERATING SEGMENTS
    TABLE 131.ALKERMES, INC.: PRODUCT PORTFOLIO
    TABLE 132.ALKERMES, INC.: NET SALES,
    TABLE 133.ALKERMES, INC.: KEY STRATERGIES
    TABLE 134.ASTRAZENECA PLC: COMPANY SNAPSHOT
    TABLE 135.ASTRAZENECA PLC: OPERATING SEGMENTS
    TABLE 136.ASTRAZENECA PLC: PRODUCT PORTFOLIO
    TABLE 137.ASTRAZENECA PLC: NET SALES,
    TABLE 138.ASTRAZENECA PLC: KEY STRATERGIES
    TABLE 139.BIODELIVERY SCIENCES INTERNATIONAL INC.,: COMPANY SNAPSHOT
    TABLE 140.BIODELIVERY SCIENCES INTERNATIONAL INC.,: OPERATING SEGMENTS
    TABLE 141.BIODELIVERY SCIENCES INTERNATIONAL INC.,: PRODUCT PORTFOLIO
    TABLE 142.BIODELIVERY SCIENCES INTERNATIONAL INC.,: NET SALES,
    TABLE 143.BIODELIVERY SCIENCES INTERNATIONAL INC.,: KEY STRATERGIES
    TABLE 144.BRAEBURN PHARMACEUTICALS: COMPANY SNAPSHOT
    TABLE 145.BRAEBURN PHARMACEUTICALS: OPERATING SEGMENTS
    TABLE 146.BRAEBURN PHARMACEUTICALS: PRODUCT PORTFOLIO
    TABLE 147.BRAEBURN PHARMACEUTICALS: NET SALES,
    TABLE 148.BRAEBURN PHARMACEUTICALS: KEY STRATERGIES
    TABLE 149.CAMURUS: COMPANY SNAPSHOT
    TABLE 150.CAMURUS: OPERATING SEGMENTS
    TABLE 151.CAMURUS: PRODUCT PORTFOLIO
    TABLE 152.CAMURUS: NET SALES,
    TABLE 153.CAMURUS: KEY STRATERGIES
    TABLE 154.DR REDDY LABORATORIES LTD: COMPANY SNAPSHOT
    TABLE 155.DR REDDY LABORATORIES LTD: OPERATING SEGMENTS
    TABLE 156.DR REDDY LABORATORIES LTD: PRODUCT PORTFOLIO
    TABLE 157.DR REDDY LABORATORIES LTD: NET SALES,
    TABLE 158.DR REDDY LABORATORIES LTD: KEY STRATERGIES
    TABLE 159.PEAR THERAPEUTICS: COMPANY SNAPSHOT
    TABLE 160.PEAR THERAPEUTICS: OPERATING SEGMENTS
    TABLE 161.PEAR THERAPEUTICS: PRODUCT PORTFOLIO
    TABLE 162.PEAR THERAPEUTICS: NET SALES,
    TABLE 163.PEAR THERAPEUTICS: KEY STRATERGIES
    TABLE 164.HIKMA PHARMACEUTICALS PLC,: COMPANY SNAPSHOT
    TABLE 165.HIKMA PHARMACEUTICALS PLC,: OPERATING SEGMENTS
    TABLE 166.HIKMA PHARMACEUTICALS PLC,: PRODUCT PORTFOLIO
    TABLE 167.HIKMA PHARMACEUTICALS PLC,: NET SALES,
    TABLE 168.HIKMA PHARMACEUTICALS PLC,: KEY STRATERGIES
    TABLE 169.MALLINCKRODT PHARMACEUTICALS: COMPANY SNAPSHOT
    TABLE 170.MALLINCKRODT PHARMACEUTICALS: OPERATING SEGMENTS
    TABLE 171.MALLINCKRODT PHARMACEUTICALS: PRODUCT PORTFOLIO
    TABLE 172.MALLINCKRODT PHARMACEUTICALS: NET SALES,
    TABLE 173.MALLINCKRODT PHARMACEUTICALS: KEY STRATERGIES
    TABLE 174.NYC HEALTH HOSPITALS: COMPANY SNAPSHOT
    TABLE 175.NYC HEALTH HOSPITALS: OPERATING SEGMENTS
    TABLE 176.NYC HEALTH HOSPITALS: PRODUCT PORTFOLIO
    TABLE 177.NYC HEALTH HOSPITALS: NET SALES,
    TABLE 178.NYC HEALTH HOSPITALS: KEY STRATERGIES
    TABLE 179.OREXO AB: COMPANY SNAPSHOT
    TABLE 180.OREXO AB: OPERATING SEGMENTS
    TABLE 181.OREXO AB: PRODUCT PORTFOLIO
    TABLE 182.OREXO AB: NET SALES,
    TABLE 183.OREXO AB: KEY STRATERGIES
    TABLE 184.OREXO AB: COMPANY SNAPSHOT
    TABLE 185.OREXO AB: OPERATING SEGMENTS
    TABLE 186.OREXO AB: PRODUCT PORTFOLIO
    TABLE 187.OREXO AB: NET SALES,
    TABLE 188.OREXO AB: KEY STRATERGIES
    TABLE 189.INDIVIOR PLC: COMPANY SNAPSHOT
    TABLE 190.INDIVIOR PLC: OPERATING SEGMENTS
    TABLE 191.INDIVIOR PLC: PRODUCT PORTFOLIO
    TABLE 192.INDIVIOR PLC: NET SALES,
    TABLE 193.INDIVIOR PLC: KEY STRATERGIES
    TABLE 194.RECKITT BENCKISER PHARMACEUTICALS INC: COMPANY SNAPSHOT
    TABLE 195.RECKITT BENCKISER PHARMACEUTICALS INC: OPERATING SEGMENTS
    TABLE 196.RECKITT BENCKISER PHARMACEUTICALS INC: PRODUCT PORTFOLIO
    TABLE 197.RECKITT BENCKISER PHARMACEUTICALS INC: NET SALES,
    TABLE 198.RECKITT BENCKISER PHARMACEUTICALS INC: KEY STRATERGIES
    TABLE 199.SANDOZ: COMPANY SNAPSHOT
    TABLE 200.SANDOZ: OPERATING SEGMENTS
    TABLE 201.SANDOZ: PRODUCT PORTFOLIO
    TABLE 202.SANDOZ: NET SALES,
    TABLE 203.SANDOZ: KEY STRATERGIES
    TABLE 204.TITAN PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
    TABLE 205.TITAN PHARMACEUTICALS, INC.: OPERATING SEGMENTS
    TABLE 206.TITAN PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
    TABLE 207.TITAN PHARMACEUTICALS, INC.: NET SALES,
    TABLE 208.TITAN PHARMACEUTICALS, INC.: KEY STRATERGIES
    TABLE 209.VIATRIS INC: COMPANY SNAPSHOT
    TABLE 210.VIATRIS INC: OPERATING SEGMENTS
    TABLE 211.VIATRIS INC: PRODUCT PORTFOLIO
    TABLE 212.VIATRIS INC: NET SALES,
    TABLE 213.VIATRIS INC: KEY STRATERGIES
  • LIST OF FIGURES

  • FIGURE 1.OPIOID USE DISORDER MARKET SEGMENTATION
    FIGURE 2.OPIOID USE DISORDER MARKET,2021-2031
    FIGURE 3.OPIOID USE DISORDER MARKET,2021-2031
    FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
    FIGURE 5.PORTER FIVE-1
    FIGURE 6.PORTER FIVE-2
    FIGURE 7.PORTER FIVE-3
    FIGURE 8.PORTER FIVE-4
    FIGURE 9.PORTER FIVE-5
    FIGURE 10.TOP PLAYER POSITIONING
    FIGURE 11.OPIOID USE DISORDER MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
    FIGURE 12.OPIOID USE DISORDER MARKET,BY DRUG TYPE,2021(%)
    FIGURE 13.COMPARATIVE SHARE ANALYSIS OF AGONIST OPIOID USE DISORDER MARKET,2021-2031(%)
    FIGURE 14.COMPARATIVE SHARE ANALYSIS OF ANTAGONIST OPIOID USE DISORDER MARKET,2021-2031(%)
    FIGURE 15.OPIOID USE DISORDER MARKET,BY AGE GROUP,2021(%)
    FIGURE 16.COMPARATIVE SHARE ANALYSIS OF 19 TO 39 OPIOID USE DISORDER MARKET,2021-2031(%)
    FIGURE 17.COMPARATIVE SHARE ANALYSIS OF 40 TO 59 OPIOID USE DISORDER MARKET,2021-2031(%)
    FIGURE 18.COMPARATIVE SHARE ANALYSIS OF AGE 60 AND OVER OPIOID USE DISORDER MARKET,2021-2031(%)
    FIGURE 19.OPIOID USE DISORDER MARKET,BY ROUTE OF ADMINISTRATION,2021(%)
    FIGURE 20.COMPARATIVE SHARE ANALYSIS OF ORAL OPIOID USE DISORDER MARKET,2021-2031(%)
    FIGURE 21.COMPARATIVE SHARE ANALYSIS OF INTRAVENOUS OPIOID USE DISORDER MARKET,2021-2031(%)
    FIGURE 22.COMPARATIVE SHARE ANALYSIS OF SUBLINGUAL OPIOID USE DISORDER MARKET,2021-2031(%)
    FIGURE 23.OPIOID USE DISORDER MARKET,BY DISTRIBUTION CHANNAL,2021(%)
    FIGURE 24.COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACY OPIOID USE DISORDER MARKET,2021-2031(%)
    FIGURE 25.COMPARATIVE SHARE ANALYSIS OF RETAIL PHARMACY OPIOID USE DISORDER MARKET,2021-2031(%)
    FIGURE 26.OPIOID USE DISORDER MARKET BY REGION,2021
    FIGURE 27.U.S. OPIOID USE DISORDER MARKET,2021-2031($MILLION)
    FIGURE 28.CANADA OPIOID USE DISORDER MARKET,2021-2031($MILLION)
    FIGURE 29.MEXICO OPIOID USE DISORDER MARKET,2021-2031($MILLION)
    FIGURE 30.GERMANY OPIOID USE DISORDER MARKET,2021-2031($MILLION)
    FIGURE 31.FRANCE OPIOID USE DISORDER MARKET,2021-2031($MILLION)
    FIGURE 32.UK OPIOID USE DISORDER MARKET,2021-2031($MILLION)
    FIGURE 33.ITALY OPIOID USE DISORDER MARKET,2021-2031($MILLION)
    FIGURE 34.SPAIN OPIOID USE DISORDER MARKET,2021-2031($MILLION)
    FIGURE 35.REST OF EUROPE OPIOID USE DISORDER MARKET,2021-2031($MILLION)
    FIGURE 36.CHINA OPIOID USE DISORDER MARKET,2021-2031($MILLION)
    FIGURE 37.JAPAN OPIOID USE DISORDER MARKET,2021-2031($MILLION)
    FIGURE 38.INDIA OPIOID USE DISORDER MARKET,2021-2031($MILLION)
    FIGURE 39.AUSTRALIA OPIOID USE DISORDER MARKET,2021-2031($MILLION)
    FIGURE 40.SOUTH KOREA OPIOID USE DISORDER MARKET,2021-2031($MILLION)
    FIGURE 41.REST OF ASIA-PACIFIC OPIOID USE DISORDER MARKET,2021-2031($MILLION)
    FIGURE 42.BRAZIL OPIOID USE DISORDER MARKET,2021-2031($MILLION)
    FIGURE 43.SAUDI ARABIA OPIOID USE DISORDER MARKET,2021-2031($MILLION)
    FIGURE 44.SOUTH AFRICA OPIOID USE DISORDER MARKET,2021-2031($MILLION)
    FIGURE 45.REST OF LAMEA OPIOID USE DISORDER MARKET,2021-2031($MILLION)
    FIGURE 46. TOP WINNING STRATEGIES, BY YEAR
    FIGURE 47. TOP WINNING STRATEGIES, BY DEVELOPMENT
    FIGURE 48. TOP WINNING STRATEGIES, BY COMPANY
    FIGURE 49.PRODUCT MAPPING OF TOP 10 PLAYERS
    FIGURE 50.COMPETITIVE DASHBOARD
    FIGURE 51.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
    FIGURE 52.ALKERMES, INC..: NET SALES ,($MILLION)
    FIGURE 53.ASTRAZENECA PLC.: NET SALES ,($MILLION)
    FIGURE 54.BIODELIVERY SCIENCES INTERNATIONAL INC.,.: NET SALES ,($MILLION)
    FIGURE 55.BRAEBURN PHARMACEUTICALS.: NET SALES ,($MILLION)
    FIGURE 56.CAMURUS.: NET SALES ,($MILLION)
    FIGURE 57.DR REDDY LABORATORIES LTD.: NET SALES ,($MILLION)
    FIGURE 58.PEAR THERAPEUTICS.: NET SALES ,($MILLION)
    FIGURE 59.HIKMA PHARMACEUTICALS PLC,.: NET SALES ,($MILLION)
    FIGURE 60.MALLINCKRODT PHARMACEUTICALS.: NET SALES ,($MILLION)
    FIGURE 61.NYC HEALTH HOSPITALS.: NET SALES ,($MILLION)
    FIGURE 62.OREXO AB.: NET SALES ,($MILLION)
    FIGURE 63.OREXO AB.: NET SALES ,($MILLION)
    FIGURE 64.INDIVIOR PLC.: NET SALES ,($MILLION)
    FIGURE 65.RECKITT BENCKISER PHARMACEUTICALS INC.: NET SALES ,($MILLION)
    FIGURE 66.SANDOZ.: NET SALES ,($MILLION)
    FIGURE 67.TITAN PHARMACEUTICALS, INC..: NET SALES ,($MILLION)
    FIGURE 68.VIATRIS INC.: NET SALES ,($MILLION)

 
 

Opioid use disorder consists of an overpowering desire to use opioids, increased opioid tolerance, and withdrawal syndrome when discontinued. The opioid use disorder market is expected to witness growth during the forecast period owing to, rise in the prevalence of chronic diseases such as cardiovascular disease, cancer and others, increase in the product launch and product approval for opioids use disorder drugs and increasing cases of opioid addiction.

Rise in adoption of key strategies such as collaboration, acquisition, agreement and partnership by key players of opioids use disorder fuels the growth of market. For instance, in February 2019, Indivior PLC, a pharmaceutical company, announced agreement with Alvogen Pine Brook LLC, a pharmaceutical company for sell of generic buprenorphine and naloxone sublingual film product unless and until the U.S. Moreover, in February 2021, Orexo AB announced its collaboration with ApexB.io biotechnology research company to further research on the use of Modia. This product is a digital therapeutic designed for patients with opioid use disorder

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com
 
FREQUENTLY ASKED QUESTIONS?

A. The top companies that hold the market share in opioid use disorder market are increase in number of patients suffering from wide range of severe and chronic diseases such as cancer, cardiovascular disease, pain arising from injuries and other conditions

A. Asia-Pacific is expected to register highest CAGR of 12.3% from 2022 to 2031, owing to the number of geriatric populations, rise in the awareness regarding availability of healthcare services and increase in the number of chronic diseases.

A. The key trends in the opioid use disorder market are Alkermes, AstraZeneca Plc., BioDelivery Sciences International Inc., Braeburn, Camurus, Cerebral, Dr Reddy, Hikma Pharmaceuticals PLC, Indivior PLC, Mallinckrodt Pharmaceuticals, NYC Health + Hospitals, Orexo AB, Pear Therapeutics, Pfizer, Reckitt Benckiser Pharmaceuticals Inc., Sandoz (Novartis), Titan Pharmaceuticals, Inc., and Viatris Inc.,

A. Yes, opioid use disorder companies are profiled in the report

A. The total market value of opioid use disorder market is $2,750.5 million in 2021.

A. The forecast period in the report is from 2022 to 2031

A. The market value of opioid use disorder market in 2022 was $3,059.4 million

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Request Sample
RELATED TAGS

Purchase Full Report of
Opioid Use Disorder Market

Start reading instantly.
This Report and over 66,804+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,840
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
    (Aug 2023 - Aug 2024)
  • Data Pack
  • $4,380
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Aug 2023 - Aug 2024)
  • Single User
  • $6,090
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Aug 2023 - Aug 2024)
  • Five Users
  • $6,630
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Aug 2023 - Aug 2024)
  • Enterprise
    License/PDF

  • $10,500
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Aug 2023 - Aug 2024)
  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers